Professor Mike Owen

Mike Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for over 40 years.

He currently serves as a director on four boards. He is the Chairman of Ossianix Inc, a privately held biotechnology company, and is also on the boards of Zealand Pharma A/S, ReNeuron plc and Sareum Holdings plc.

Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs. Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company, recently acquired by Sanofi. Prior to co-founding Kymab, Dr Owen worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Prior to joining the Pharma industry, Dr Owen was a Principal Scientist at the ICRF London laboratories (now CR-UK) where he was noted for his work on lymphocyte development and on the molecular basis of diversity in the adaptive immune system.

Dr Owen received a BA degree from Oxford University in 1973 and a PhD from Cambridge University in 1976. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.